PE20211776A1 - Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer - Google Patents

Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer

Info

Publication number
PE20211776A1
PE20211776A1 PE2021000726A PE2021000726A PE20211776A1 PE 20211776 A1 PE20211776 A1 PE 20211776A1 PE 2021000726 A PE2021000726 A PE 2021000726A PE 2021000726 A PE2021000726 A PE 2021000726A PE 20211776 A1 PE20211776 A1 PE 20211776A1
Authority
PE
Peru
Prior art keywords
octan
triazol
alzheimer
dihydro
gamma
Prior art date
Application number
PE2021000726A
Other languages
English (en)
Inventor
Beat Frei
Hasane Ratni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20211776A1 publication Critical patent/PE20211776A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un compuesto de formula (I) donde R 1 es halogeno; m es 1,2 o 3; n es 1, 2, 3; Ar es un grupo heteroarilo de seis miembros. Los presentes compuestos son como moduladores de gamma-secretasa para el tratamiento de enfermedades asociadas al deposito de beta-amiloide en el cerebro, tales como enfermedad de Alzheimer, hipoacusia, demencia multiinfarto, demencia pugilistica y sindrome de Down. Un compuesto de ejemplo es (R)-7-(3,5-difluorofenoxi)-N- ((1R,5S,8s)-3-(6-metoxipiridazin-4-il)-3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5Hpirrolo[1,2-b][1,2,4]triazol-2-amina.
PE2021000726A 2018-12-13 2019-12-11 Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer PE20211776A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18212199 2018-12-13
PCT/EP2019/084538 WO2020120521A1 (en) 2018-12-13 2019-12-11 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
PE20211776A1 true PE20211776A1 (es) 2021-09-08

Family

ID=64665266

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000726A PE20211776A1 (es) 2018-12-13 2019-12-11 Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer

Country Status (19)

Country Link
US (1) US20220056036A1 (es)
EP (1) EP3894411B1 (es)
JP (1) JP2022513466A (es)
KR (1) KR20210102900A (es)
CN (2) CN113179641B (es)
AR (1) AR116906A1 (es)
AU (1) AU2019395774A1 (es)
BR (1) BR112021009443A2 (es)
CA (1) CA3117870A1 (es)
CL (1) CL2021001547A1 (es)
CO (1) CO2021006837A2 (es)
CR (1) CR20210305A (es)
IL (2) IL283823B1 (es)
MA (1) MA54447A (es)
MX (1) MX2021006761A (es)
PE (1) PE20211776A1 (es)
SG (1) SG11202103340PA (es)
TW (1) TWI831892B (es)
WO (1) WO2020120521A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703763B2 (en) * 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
CN107922437B (zh) * 2015-09-09 2021-12-10 豪夫迈·罗氏有限公司 桥连哌啶衍生物
EP3386978B1 (en) * 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
WO2018001918A1 (en) * 2016-06-27 2018-01-04 F. Hoffmann-La Roche Ag Triazolopyridines as gamma-secretase modulators
AR110001A1 (es) * 2016-11-01 2019-02-13 Hoffmann La Roche Derivados heteroarilo bicíclicos
WO2018087018A1 (en) * 2016-11-08 2018-05-17 F. Hoffmann-La Roche Ag Phenoxytriazoles
RU2757276C2 (ru) 2016-12-16 2021-10-12 Пайплайн Терапьютикс, Инк. Способы лечения кохлеарной синаптопатии

Also Published As

Publication number Publication date
CA3117870A1 (en) 2020-06-18
KR20210102900A (ko) 2021-08-20
CO2021006837A2 (es) 2021-06-10
BR112021009443A2 (pt) 2021-08-17
EP3894411A1 (en) 2021-10-20
CL2021001547A1 (es) 2021-12-24
WO2020120521A1 (en) 2020-06-18
CN117946116A (zh) 2024-04-30
MA54447A (fr) 2022-03-23
MX2021006761A (es) 2021-07-15
US20220056036A1 (en) 2022-02-24
AR116906A1 (es) 2021-06-23
TW202039499A (zh) 2020-11-01
SG11202103340PA (en) 2021-04-29
TWI831892B (zh) 2024-02-11
IL283823A (en) 2021-07-29
CR20210305A (es) 2021-07-20
AU2019395774A1 (en) 2021-04-08
EP3894411B1 (en) 2024-06-19
CN113179641A (zh) 2021-07-27
IL283823B1 (en) 2024-03-01
CN113179641B (zh) 2024-01-02
JP2022513466A (ja) 2022-02-08
IL310081A (en) 2024-03-01

Similar Documents

Publication Publication Date Title
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
EA201891463A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ (JAK)
PH12015501878A1 (en) Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative
PH12015502502A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
AR069510A1 (es) Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10
AR070130A1 (es) Compuestos moduladores de beta-amiloide, un proceso para su obtencion, el uso del compuesto para la fabricacion de un medicamento y dicho medicamento
AU2018253590A1 (en) Imidazopyridazine compounds
PL3625233T3 (pl) Pochodne 3-(((((2s,5r)-2-karbamoilo-7-okso-1,6-diazabicyklo[3.2.1]oktan-6-ylo)oksy)sulfonylo)oksy)-2,2-dimetylopropanianowe i związki pokrewne jako doustnie podawane proleki inhibitorów beta-laktamaz do leczenia zakażeń bakteryjnych
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
EA201691046A1 (ru) Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4)
AR100713A1 (es) Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor
NZ628969A (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
EA201590438A1 (ru) 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы
AR086036A1 (es) DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5)
CL2020002157A1 (es) Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas.
PH12016501481B1 (en) Ethynyl derivatives
MX2017005715A (es) Potentes moduladores de gamma-secretasa.
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
PE20190778A1 (es) Derivados de eter ciclico de pirazolo[1,5-a]pirimidin-3-carboxiamida
PE20211776A1 (es) Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer
PE20221454A1 (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4
MX2013014662A (es) Derivados de sulfonamida de aminas aliciclicas para el tratamiento de enfermedades del sistema nervioso central.
PE20150341A1 (es) Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona
AR121666A1 (es) DERIVADOS DE NAFTIRIDINA Y PIRIDO[3,4-C]PIRIDAZINA COMO MODULADORES DEL RECEPTOR GABAA a5